Aspen picks up piece of GSK OTC biz for $263M; Watson ships generic Fortamet;

 @FiercePharma: China shuts down 10 drug capsulemakers. Article | Follow @FiercePharma

> South Africa's Aspen Pharmacare ($LDZA.F) will pay GlaxoSmithKline ($GSK) $263 million for a variety of over-the-counter brands as GSK continues to divest that business. Story

> Watson Pharmaceuticals ($WPI) is shipping a generic version of Shionogi's Fortamet, a treatment for lowering glucose, under an agreement with that company. Item

> The FDA has sent a second warning about the unapproved Brilliant Blue G made by Franck's Pharmacy after more reports of patients getting fungal eye infections. Alert

> In an alert about the dangers of fentanyl, the FDA points out that 26 children under the age of 2 have died since 1997 from accidental exposure to the painkiller patches. Story

> CVS Caremark will cough up $13.75 million to California to get out from under claims it illegally dumped hazardous waste, including pharmaceuticals, at California stores. Story

Biotech News

 @FierceBiotech: European committee backs AZ, BMS and Novartis drugs for approval. Article | Follow @FierceBiotech

 @JohnCFierce: Alnylam reports Phase I efficacy data on its PCSK9 program. Item | Follow @JohnCFierce

 @RyanMFierce: GAO report says the FDA's IT is behind the times. Not news to many of you, though. Report | Follow @RyanMFierce

> Readers' picks, responses to Fierce's 'Top 10' cancer drugs report. More

> FDA hits brakes on Novartis' hep C program after death. Story

> Alnylam scores efficacy data with PCSK9 drug. News

> FDA hits brakes on Novartis' hep C program after death. Article

Medical Devices News

 @FierceMedDev: Olympus looks to push past scandal, but can it? News | Follow @FierceMedDev

> Top 10 Medical Device R&D Budgets. Special report

> emPower maker PixelOptics raises $7M. Article

> GI Dynamics' EndoBarrier implanted in first patients, stock soars. More

And Finally... Par Pharmaceuticals ($PRX) will get a percent of the profits but all of the responsibility for litigation in Northern California under an agreement with Handa Pharmaceuticals to acquire exclusive rights to buy its ANDA for dexlansoprazole capsules, itself a generic version of Takeda's Dexilant. Item

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.